Bard Diagnostic's bladder cancer test cleared by FDA:
This article was originally published in Clinica
Bard Diagnostic Sciences, a division of CR Bard, has received clearance from the FDA to market its BTA stat test in the US. The test detects bladder cancer with the technology found in one-step pregnancy tests. The company estimates that the test could benefit an estimated 48 million smokers in the US. Smokers experience twice the risk of bladder cancer as nonsmokers. Bladder cancer strikes almost 53,000 people in the US each year, and more than 250,000 people are routinely monitored for the disease, estimates the American Cancer Society.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.